Start-ups : the success stories

Positioning itself as a leader in GPCR-based immuno-oncology, Domain takes a unique approach, using precise biomarkers to address the individual needs of patients based on the unique characteristics of their cancer. With two decades of solid expertise in GPCR-targeted drug discovery, backed by multiple pharmaceutical partnerships and a state-of-the-art platform for target identification and discovery, Domain is improving understanding of cancer and bringing breakthrough immunotherapies to patients.

Domain’s proprietary programs include DT-7012, an antibody inhibiting CCR8 to suppress Tregs; DT-9045, the first-in-class negative allosteric modulator of PAR2; DT-9081, an EP4 receptor antagonist; and M1069, an A2aR/A2b receptor antagonist, identified in collaboration with Merck KGaA. The company also boasts a rich pipeline of first-class GPCR targets, selected through a proprietary, state-of-the-art drug discovery and development platform.